 |
 |
| December 27, 2011 |
Proteonomix, Inc. |
 |
Proteonomix, Inc. (PROT) Announces Completion of Payment for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease. |
 |
MOUNTAINSIDE, NJ--(Marketwire -12/27/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has completed all payments required from Proteonomix to commence a Clinical Study entitled "UMK-121 in Patients with Liver Disease." |
|
| Read Full Story > |
|
 |
| December 7, 2011 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Letter to Shareholders. |
|
Dear Shareholders: This has been a momentous year for your Company. During the past several years we have asserted that our business lines would move forward in both the cosmetic area via our Proteoderm subsidiary and in the biopharmaceutical lines, most recently our UMK-121 technology. |
|
| Read Full Story > |
|
